Keros Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell KROS and other ETFs, options, and stocks.

About KROS

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. 

CEO
Jasbir S. Seehra
CEOJasbir S. Seehra
Employees
169
Employees169
Headquarters
Lexington, Massachusetts
HeadquartersLexington, Massachusetts
Founded
2015
Founded2015
Employees
169
Employees169

KROS Key Statistics

Market cap
634.61M
Market cap634.61M
Price-Earnings ratio
13.96
Price-Earnings ratio13.96
Dividend yield
Dividend yield
Average volume
867.13K
Average volume867.13K
High today
$22.10
High today$22.10
Low today
$20.66
Low today$20.66
Open price
$21.68
Open price$21.68
Volume
471.79K
Volume471.79K
52 Week high
$22.55
52 Week high$22.55
52 Week low
$9.12
52 Week low$9.12

Stock Snapshot

With a market cap of 634.61M, Keros Therapeutics(KROS) trades at $20.83. The stock has a price-to-earnings ratio of 13.96.

On 2025-12-17, Keros Therapeutics(KROS) stock moved within a range of $20.66 to $22.10. With shares now at $20.83, the stock is trading +0.8% above its intraday low and -5.7% below the session's peak.

Trading activity shows a volume of 471.79K, compared to an average daily volume of 867.13K.

The stock's 52-week range extends from a low of $9.12 to a high of $22.55.

The stock's 52-week range extends from a low of $9.12 to a high of $22.55.

Analyst ratings

56%

of 9 ratings
Buy
55.6%
Hold
44.4%
Sell
0%

People also own

Based on the portfolios of people who own KROS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.